Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
Search
Advanced Search
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Clinical trial methodology"

Article category

Keywords

More +

Publication year

"Clinical trial methodology"

Letters to the Editor
“Surrogates without substance?” Questioning the evidence for histologic improvement with HTD1801: Letter to the editor on “HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study”
Zhihao Lei
Clin Mol Hepatol 2026;32(2):e158-e160.
Published online August 19, 2025
DOI: https://doi.org/10.3350/cmh.2025.0868

Citations

Citations to this article as recorded by  Crossref logo
  • Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial
    Jiajia Mai, Hong Zhang, Min Wu, Meng Yu, Kui Liu, Guixia Wang, Yanhua Ding
    Diabetology & Metabolic Syndrome.2026;[Epub]     CrossRef
  • Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular–Kidney–Metabolic Disease: A Narrative Review
    Boknyun Kim, Joseph Kim, Grace Kim, Kitai Kim
    Pharmaceuticals.2026; 19(10): 1572.     CrossRef
  • 3,560 View
  • 77 Download
  • 1 Web of Science
  • Crossref
Letter to the editor on “HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study”
Xi-Lin Gao
Clin Mol Hepatol 2026;32(2):e161-e162.
Published online August 19, 2025
DOI: https://doi.org/10.3350/cmh.2025.0804
  • 4,376 View
  • 62 Download
First First Prev Prev
Page of 1
Next Next Last Last
Clin Mol Hepatol : Clinical and Molecular Hepatology
Twitter